findmyKOL
Clinical trialNCT05243511CompletedPhase 3Interventional

Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management

SponsorSwing Therapeutics, Inc.Enrollment275Fibromyalgia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

PROSPER-FM is a multi-center, randomized, non-significant risk device study to evaluate the safety and efficacy of two digital therapy smartphone applications in participants with fibromyalgia. Eligible participants are randomized (1:1) to either the Digital Acceptance and Commitment Therapy (Digital ACT) group or the Digital Symptom Tracker group and receive assigned therapy for 12 weeks.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Site #37

    Covina, California, United States

  • Site #15

    Oceanside, California, United States

  • Site #31

    San Bernardino, California, United States

  • Site #38

    Thousand Oaks, California, United States

  • Site #36

    Tujunga, California, United States

  • Site #35

    Whittier, California, United States

  • Site #13

    Orlando, Florida, United States

  • Site #33

    St. Petersburg, Florida, United States

  • Site #25

    Atlanta, Georgia, United States

  • Site #21

    Covington, Louisiana, United States

  • Site #20

    New Orleans, Louisiana, United States

  • Site #22

    Prairieville, Louisiana, United States

  • Site #39

    Chestnut Hill, Massachusetts, United States

  • Site #24

    Ocean Springs, Mississippi, United States

  • Site #34

    Brooklyn, New York, United States

  • Site #32

    Scarsdale, New York, United States

  • Site #12

    Williamsville, New York, United States

  • Site #27

    Fargo, North Dakota, United States

  • Site #14

    Cincinnati, Ohio, United States

  • Site #28

    Dayton, Ohio, United States

  • Site #23

    Tulsa, Oklahoma, United States

  • Site #16

    Allentown, Pennsylvania, United States

  • Site #29

    Austin, Texas, United States

  • Site #26

    McKinney, Texas, United States

  • Site #30

    Pflugerville, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Feb 2022
Primary completion
15 May 2023
Completion
15 May 2023
Last update posted
15 Jun 2023
Registered enrollment
275
Registry id
NCT05243511
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.